JP2013500255A - 自食作用の強力な小分子阻害剤、およびそれの使用方法 - Google Patents

自食作用の強力な小分子阻害剤、およびそれの使用方法 Download PDF

Info

Publication number
JP2013500255A
JP2013500255A JP2012521755A JP2012521755A JP2013500255A JP 2013500255 A JP2013500255 A JP 2013500255A JP 2012521755 A JP2012521755 A JP 2012521755A JP 2012521755 A JP2012521755 A JP 2012521755A JP 2013500255 A JP2013500255 A JP 2013500255A
Authority
JP
Japan
Prior art keywords
autophagy
cancer
lower alkyl
compound according
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012521755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500255A5 (enExample
Inventor
ユエン，ジュンイン
マー，ダーウェイ
リウ，ジュンリー
ヂャン，リホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42829077&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013500255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Harvard University filed Critical Harvard University
Publication of JP2013500255A publication Critical patent/JP2013500255A/ja
Publication of JP2013500255A5 publication Critical patent/JP2013500255A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2012521755A 2009-07-21 2010-07-21 自食作用の強力な小分子阻害剤、およびそれの使用方法 Pending JP2013500255A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22716409P 2009-07-21 2009-07-21
US61/227,164 2009-07-21
US29673510P 2010-01-20 2010-01-20
US61/296,735 2010-01-20
PCT/US2010/042759 WO2011011522A2 (en) 2009-07-21 2010-07-21 Potent small molecule inhibitors of autophagy, and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2013500255A true JP2013500255A (ja) 2013-01-07
JP2013500255A5 JP2013500255A5 (enExample) 2013-08-22

Family

ID=42829077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012521755A Pending JP2013500255A (ja) 2009-07-21 2010-07-21 自食作用の強力な小分子阻害剤、およびそれの使用方法

Country Status (18)

Country Link
US (1) US20120258975A1 (enExample)
EP (1) EP2456761A2 (enExample)
JP (1) JP2013500255A (enExample)
KR (1) KR20120100886A (enExample)
CN (1) CN102574816A (enExample)
AU (1) AU2010276223A1 (enExample)
BR (1) BR112012001316A2 (enExample)
CA (1) CA2767772A1 (enExample)
CL (1) CL2012000163A1 (enExample)
IL (1) IL217502A0 (enExample)
IN (1) IN2012DN01478A (enExample)
MX (1) MX2012000940A (enExample)
PE (1) PE20120798A1 (enExample)
PH (1) PH12012500097A1 (enExample)
RU (1) RU2012105914A (enExample)
SG (1) SG177486A1 (enExample)
WO (1) WO2011011522A2 (enExample)
ZA (1) ZA201201224B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504365A (ja) * 2012-12-28 2016-02-12 アメリカ合衆国 Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用
JP2018515507A (ja) * 2015-05-08 2018-06-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法
JP2019529514A (ja) * 2015-10-05 2019-10-17 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーフラックス及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
JP2020505454A (ja) * 2017-01-17 2020-02-20 リヴァプール スクール オブ トロピカル メディスン 化合物
JP2024504587A (ja) * 2021-01-14 2024-02-01 ジョージタウン ユニバーシティ Ｕｓｐ１３阻害剤及びその使用方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504586A (ja) 2009-09-10 2013-02-07 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 脱ユビキチン化酵素およびユビキチン化ポリペプチドを調節するための方法および材料
US8598344B2 (en) * 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013040153A1 (en) * 2011-09-13 2013-03-21 Igor Roninson TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
CA3217159A1 (en) 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
JP6301374B2 (ja) 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
EP2961409A1 (en) * 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
US9393244B2 (en) 2013-03-15 2016-07-19 Georgetown University Increasing parkin activity by administering a deubiquitinating enzyme inhibitor
WO2014145512A2 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Potent small molecule inhibitors of autophagy, and methods of use thereof
JP2016517439A (ja) * 2013-03-15 2016-06-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 医学的状態の治療のためのクロマチン修飾因子の標的化
US10563225B2 (en) * 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
CN104164471A (zh) * 2013-11-04 2014-11-26 复旦大学 基于细胞自噬的抗肿瘤药物的筛选方法
EP3184514A1 (en) * 2015-12-23 2017-06-28 Deutsches Krebsforschungszentrum Autophagy inhibitors
CN108929373A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一种共价键修饰哺乳动物atg8 同源物的方法
JP7633676B2 (ja) 2018-07-26 2025-02-20 ドメイン・セラピューティクス 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
CN109721554A (zh) * 2019-01-08 2019-05-07 贵州大学 一类4-氨基喹唑啉类化合物及其制备方法和应用
PE20220597A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
EP4295846A3 (en) 2019-05-10 2024-02-28 Deciphera Pharmaceuticals, LLC Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
CA3143489A1 (en) * 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
US20210215710A1 (en) * 2019-12-23 2021-07-15 University Health Network Methods for use of cdx2 as a biomarker to guide use of autophagy inhibitors in ovarian cancer
CN115485385A (zh) 2020-03-04 2022-12-16 瑞泽恩制药公司 用于使肿瘤细胞对免疫疗法敏感的方法和组合物
CN112608302B (zh) * 2020-12-28 2022-05-24 郑州大学第一附属医院 低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用
US11648254B2 (en) 2021-03-02 2023-05-16 Kumquat Biosciences Inc. Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling
WO2023034411A1 (en) 2021-09-01 2023-03-09 Oerth Bio Llc Compositions and methods for targeted degradation of proteins in a plant cell
CN114224895B (zh) * 2022-01-06 2023-06-30 山东农业大学 3-甲基腺嘌呤在清除牛乳腺上皮细胞内无乳链球菌中的应用
EP4511128A1 (en) 2022-04-20 2025-02-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
CN116179494B (zh) * 2022-10-13 2024-01-26 武汉生物制品研究所有限责任公司 低成瘤性的mdck细胞株及其构建方法和应用
DE102022131212A1 (de) 2022-11-25 2024-05-29 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Luftzufuhrvorrichtung einer Kraftfahrzeugkarosserie eines Kraftfahrzeugs

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS542325A (en) * 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
JPS542327A (en) * 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
JPH01226877A (ja) * 1988-01-29 1989-09-11 Eli Lilly & Co キナゾリン誘導体
JPH01246264A (ja) * 1988-01-29 1989-10-02 Eli Lilly & Co キノリン、キナゾリンおよびシンノリン誘導体
JPH0366689A (ja) * 1989-07-27 1991-03-22 Eli Lilly & Co ピリドピリミジン誘導体
WO1993004583A1 (en) * 1991-09-03 1993-03-18 Dowelanco Nematicidal method
JPH1095776A (ja) * 1991-09-30 1998-04-14 Eisai Co Ltd 含窒素複素環化合物
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
WO2003066602A1 (en) * 2002-02-06 2003-08-14 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
JP2004517048A (ja) * 2000-08-26 2004-06-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト キナゾリン誘導体、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法
JP2007523177A (ja) * 2004-02-19 2007-08-16 レクサーン コーポレーション キナゾリン誘導体およびキナゾリン誘導体の治療への使用
JP2008526734A (ja) * 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004059454A (ja) * 2002-07-25 2004-02-26 Japan Energy Corp キナゾリン誘導体及びＮＦ−κＢ活性化阻害剤
EP1856247B1 (en) 2005-01-19 2016-05-04 The Trustees of The University of Pennsylvania Regulation of autophagy and cell survival
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS542325A (en) * 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
JPS542327A (en) * 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
JPH01226877A (ja) * 1988-01-29 1989-09-11 Eli Lilly & Co キナゾリン誘導体
JPH01246264A (ja) * 1988-01-29 1989-10-02 Eli Lilly & Co キノリン、キナゾリンおよびシンノリン誘導体
JPH0366689A (ja) * 1989-07-27 1991-03-22 Eli Lilly & Co ピリドピリミジン誘導体
WO1993004583A1 (en) * 1991-09-03 1993-03-18 Dowelanco Nematicidal method
JPH1095776A (ja) * 1991-09-30 1998-04-14 Eisai Co Ltd 含窒素複素環化合物
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
JP2004517048A (ja) * 2000-08-26 2004-06-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト キナゾリン誘導体、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法
WO2003066602A1 (en) * 2002-02-06 2003-08-14 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
JP2007523177A (ja) * 2004-02-19 2007-08-16 レクサーン コーポレーション キナゾリン誘導体およびキナゾリン誘導体の治療への使用
JP2008526734A (ja) * 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
JPN5012018592; ＲＩＮＤＥＲＳＰＡＣＨＥＲ　Ａ: 'ＰＯＴＥＮＴ　ＩＮＨＩＢＩＴＯＲＳ　ＯＦ　ＨＵＮＴＩＮＧＴＩＮ　ＰＲＯＴＥＩＮ　ＡＧＧＲＥＧＡＴＩＯＮ　ＩＮ　Ａ　ＣＥＬＬ-ＢＡＳＥＤ　ＡＳＳＡＹ' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ Ｖ１９　Ｎ６, 20090315, Ｐ１７１５-１７１７, ＰＥＲＧＡＭＯＮ，　ＥＬＳＥＶＩＥＲ　ＳＣＩＥＮＣＥ *
JPN5012018595; ＬＩ　ＱＩＡＮ: '３Ｄ-ＱＳＡＲ　ＡＮＤ　ＤＯＣＫＩＮＧ　ＳＴＵＤＩＥＳ　ＯＦ　ＱＵＩＮＡＺＯＬＩＮＥ　ＤＥＲＩＶＡＴＩＶＥＳ　ＷＩＴＨ　ＴＨＥ　ＩＮＨＩＢＩＴＯＲＹ　ＡＣＴＩＶＩＴＹ　ＴＯＷＡＲＤ　ＮＦ-kappaＢ' ＱＳＡＲ　＆　ＣＯＭＢＩＮＡＴＯＲＩＡＬ　ＳＣＩＥＮＣＥ Ｖ２７　Ｎ８, 200808, Ｐ９８４-９９５ *
JPN5012018598; ＷＵ　Ｗ: 'ＱＵＡＮＴＩＴＡＴＩＶＥ　ＳＴＲＵＣＴＵＲＥ-ＡＣＴＩＶＩＴＹ　ＲＥＬＡＴＩＯＮＳＨＩＰ　ＯＦ　ＱＵＩＮＡＺＯＬＩＮＥ　ＤＥＲＩＶＡＴＩＶＥＳ　以下備考' ＨＵＡＸＵＥ　ＷＵＬＩ　ＸＵＥＢＡＯ　-　ＣＨＩＮＥＳＥ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＨＥＭＩＣＡＬ　ＰＨＹＳＩＣＳ Ｖ１８　Ｎ６, 20051201, Ｐ９３６-９４０, ＵＮＩＶＥＲＳＩＴＹ　ＯＦ　ＳＣＩＥＮＣＥ　ＡＮＤ　ＴＥＣＨＮＯＬＯＧＹ　ＯＦ　ＣＨＩＮＡ *
JPN6014030038; Ｓｏｖａｎ　Ｓａｒｋａｒ，　ｅｔ　ａｌ．: 'Ｓｍａｌｌ　ｍｏｌｅｃｕｌｅｓ　ｅｎｈａｎｃｅ　ａｕｔｏｐｈａｇｙ　ａｎｄ　ｒｅｄｕｃｅ　ｔｏｘｉｃｉｔｙ　ｉｎ　Ｈｕｎｔｉｎｇｔｏｎ'ｓ　ｄｉｓｅａｓｅ　ｍｏｄｅｌｓ' Ｎａｔｕｒｅ　Ｃｈｅｍｉｃａｌ　Ｂｉｏｌｏｇｙ Ｖｏｌ．３，　Ｎｏ．６, 2007, ｐｐ．３３１-３３８ *
JPN6014030041; Ｍａｓａｎｏｒｉ　Ｔｏｂｅ，　ｅｔ　ａｌ．: 'Ｄｉｓｃｏｖｅｒｙ　ｏｆ　ｑｕｉｎａｚｏｌｉｎｅｓ　ａｓ　ａ　ｎｏｖｅｌ　ｓｔｒｕｃｔｕｒａｌ　ｃｌａｓｓ　ｏｆ　ｐｏｔｅｎｔ　ｉｎｈｉｂｉｔｏｒｓ　ｏｆ　ＮＦ-kappaＢ　ａｃｔｉｖａｔｉｏｎ' Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．１１，　Ｎｏ．３, 2003, ｐｐ．３８３-３９１ *
JPN6014030048; Ｇｕａｎｇ-Ｆａｎｇ　Ｘｕ，　ｅｔ　ａｌ．: 'Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ａｎｔｉｆｕｎｇａｌ　ａｃｔｉｖｉｔｙ　ｏｆ　ｎｏｖｅｌ　ｓ-ｓｕｂｓｔｉｔｕｔｅｄ　６-ｆｌｕｏｒｏ-４-ａｌｋｙｌ（ａｒｙｌ）ｔｈｉｏｑｕｉｎａｚｏｌｉｎｅ　ｄｅｒｉｖ' Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．１５，　Ｎｏ．１１, 2007, ｐｐ．３７６８-３７７４ *
JPN6014030049; Ｍｉｌａｄ　Ｂａｉｔｉｃｈｅ，　ｅｔ　ａｌ．: 'Ｓｙｎｔｈｅｓｉｓ　ｏｆ　ｎｅｗ　ｑｕｉｎａｚｏｌｉｎｅ　ｄｅｒｉｖａｔｉｖｅｓ' Ｈｅｔｅｒｏｃｙｃｌｉｃ　Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．１０，　Ｎｏ．４-５, 2004, ｐｐ．２６９-２７２ *
JPN7014002167; 'Ｒｅｇｉｓｔｒｙ　Ｎｏ．４７７８５５-２５-７' ＤＡＴＡＢＡＳＥ　ＲＥＧＩＳＴＲＹ　［Ｏｎｌｉｎｅ］：　Ｃｈｅｍｉｃａｌ　Ａｂｓｔｒａｃｔｓ　Ｓｅｒｖｉｃｅ，　Ｃｏｌｕｍｂｕｓ，　Ｏｈｉｏ，　ＵＳＡ．　Ｒｅｔｒｉｅｖｅｄ　ｆｒｏｍ　ＳＴＮ *
JPN7014002168; 'Ｒｅｇｉｓｔｒｙ　Ｎｏ．４７７８６１-９３-１' ＤＡＴＡＢＡＳＥ　ＲＥＧＩＳＴＲＹ　［Ｏｎｌｉｎｅ］：　Ｃｈｅｍｉｃａｌ　Ａｂｓｔｒａｃｔｓ　Ｓｅｒｖｉｃｅ，　Ｃｏｌｕｍｂｕｓ，　Ｏｈｉｏ，　ＵＳＡ．　Ｒｅｔｒｉｅｖｅｄ　ｆｒｏｍ　ＳＴＮ *
JPN7014002169; 'Ｒｅｇｉｓｔｒｙ　Ｎｏ．８８２０８３-５２-５' ＤＡＴＡＢＡＳＥ　ＲＥＧＩＳＴＲＹ　［Ｏｎｌｉｎｅ］：　Ｃｈｅｍｉｃａｌ　Ａｂｓｔｒａｃｔｓ　Ｓｅｒｖｉｃｅ，　Ｃｏｌｕｍｂｕｓ，　Ｏｈｉｏ，　ＵＳＡ．　Ｒｅｔｒｉｅｖｅｄ　ｆｒｏｍ　ＳＴＮ *
JPN7014002170; 'Ｒｅｇｉｓｔｒｙ　Ｎｏ．９３０９５６-０１-７' ＤＡＴＡＢＡＳＥ　ＲＥＧＩＳＴＲＹ　［Ｏｎｌｉｎｅ］：　Ｃｈｅｍｉｃａｌ　Ａｂｓｔｒａｃｔｓ　Ｓｅｒｖｉｃｅ，　Ｃｏｌｕｍｂｕｓ，　Ｏｈｉｏ，　ＵＳＡ．　Ｒｅｔｒｉｅｖｅｄ　ｆｒｏｍ　ＳＴＮ *
JPN7014002171; 'Ｒｅｇｉｓｔｒｙ　Ｎｏ．１０９００３８-２２-４' ＤＡＴＡＢＡＳＥ　ＲＥＧＩＳＴＲＹ　［Ｏｎｌｉｎｅ］：　Ｃｈｅｍｉｃａｌ　Ａｂｓｔｒａｃｔｓ　Ｓｅｒｖｉｃｅ，　Ｃｏｌｕｍｂｕｓ，　Ｏｈｉｏ，　ＵＳＡ．　Ｒｅｔｒｉｅｖｅｄ　ｆｒｏｍ　ＳＴＮ *
JPN7014002172; 'Ｒｅｇｉｓｔｒｙ　Ｎｏ．１０８９６２０-５８-５' ＤＡＴＡＢＡＳＥ　ＲＥＧＩＳＴＲＹ　［Ｏｎｌｉｎｅ］：　Ｃｈｅｍｉｃａｌ　Ａｂｓｔｒａｃｔｓ　Ｓｅｒｖｉｃｅ，　Ｃｏｌｕｍｂｕｓ，　Ｏｈｉｏ，　ＵＳＡ．　Ｒｅｔｒｉｅｖｅｄ　ｆｒｏｍ　ＳＴＮ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504365A (ja) * 2012-12-28 2016-02-12 アメリカ合衆国 Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用
US9802904B2 (en) 2012-12-28 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
JP2018515507A (ja) * 2015-05-08 2018-06-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法
JP2019529514A (ja) * 2015-10-05 2019-10-17 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーフラックス及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
JP2020505454A (ja) * 2017-01-17 2020-02-20 リヴァプール スクール オブ トロピカル メディスン 化合物
JP7318889B2 (ja) 2017-01-17 2023-08-01 リヴァプール スクール オブ トロピカル メディスン 化合物
JP2024504587A (ja) * 2021-01-14 2024-02-01 ジョージタウン ユニバーシティ Ｕｓｐ１３阻害剤及びその使用方法

Also Published As

Publication number Publication date
SG177486A1 (en) 2012-02-28
EP2456761A2 (en) 2012-05-30
IL217502A0 (en) 2012-02-29
AU2010276223A1 (en) 2012-03-08
PH12012500097A1 (en) 2011-01-27
US20120258975A1 (en) 2012-10-11
MX2012000940A (es) 2012-05-08
IN2012DN01478A (enExample) 2015-06-05
CL2012000163A1 (es) 2012-07-13
CN102574816A (zh) 2012-07-11
BR112012001316A2 (pt) 2017-08-08
KR20120100886A (ko) 2012-09-12
PE20120798A1 (es) 2012-07-27
RU2012105914A (ru) 2013-08-27
WO2011011522A2 (en) 2011-01-27
CA2767772A1 (en) 2011-01-27
ZA201201224B (en) 2012-10-31
WO2011011522A3 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
JP2013500255A (ja) 自食作用の強力な小分子阻害剤、およびそれの使用方法
JP2013500255A5 (enExample)
US20200352946A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
US10233187B2 (en) Fused bicyclic compounds for the treatment of disease
JP5403709B2 (ja) 新規なトリサイクリック誘導体またはその薬学的に許容可能な塩、それらの製造方法およびそれらを含む薬学的組成物
JP2022019654A (ja) がん処置のためのｋａｔ６阻害剤方法および組合せ
JP2010501593A (ja) イソキノリン、キナゾリンおよびフタラジン誘導体
US20130281398A1 (en) Treatment of diseases by epigenetic regulation
US8883763B2 (en) Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same
WO2012079079A1 (en) Production of induced pluripotent stem cells
US20210214362A1 (en) Fused bicyclic compounds for the treatment of disease
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
CA2710454A1 (en) Pyrazolo [1,5-a] pyrimidine compounds
EP2563777A2 (en) Inverse agonists and neutral antagonists for the tsh receptor
HK1171232A (en) Potent small molecule inhibitors of autophagy, and methods of use thereof
TWI458714B (zh) 苯并咪唑化合物及其用途
HK40049146A (en) Fused bicyclic compounds for the treatment of disease
HK1197679A (en) Poly (adp-ribose) polymerase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130703

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141022

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150317